Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871008 | 0.98 | GAA (0.38) | GAAPTGS2SIGMAR1CES2CES1 | |
| SCHEMBL13313635 | 0.98 | GAA (0.38) | GAAPTGS2SIGMAR1CES2CES1 | |
| SCHEMBL18215221 | 0.98 | GAA (0.38) | GAAPTGS2SIGMAR1CES2CES1 | |
| SCHEMBL12640536 | 0.95 | PTGS2 (0.38) | GAAPTGS2SIGMAR1CES2CES1 | |
| SCHEMBL2753905 | 0.87 | CYP2C19 (0.34) | GAAPTGS2SIGMAR1 | |
| SCHEMBL8482393 | 0.86 | SIGMAR1 (0.33) | SIGMAR1CNR1CNR2 | |
| SCHEMBL13193029 | 0.85 | EPHX1 (0.53) | NAAA | |
| SCHEMBL15686638 | 0.84 | KCNH3 (0.33) | SIGMAR1CNR1CNR2 | |
| SCHEMBL15686603 | 0.84 | KCNH3 (0.33) | SIGMAR1CNR1CNR2 | |
| SCHEMBL2631387 | 0.84 | KCNH3 (0.33) | SIGMAR1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2319941-A2 | Method and apparatus for correlating levels of biomarker products with disease | GeneNews Inc. (CA) | 2011-05-11 | — | — | EP | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2008137139-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | GAA 1957/4885PTGS2 2601/4885SIGMAR1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.